Although clozapine has been available for decades, there have been recent advances in
understanding how clozapine titration should be individualized based on patient-specific …

Objective Clozapine is the only approved strategy for treatment‐resistant schizophrenia,
although it is highly underutilized. We aim to generate practical and actionable evidence …

Introduction: Although clozapine (CLZ) is considered the best evidence-based therapeutic
option for treatment of resistant schizophrenia patients, a significant proportion of CLZ …

Previous studies have suggested that a delay in initiating clozapine is one of the predictors
of outcomes in treatment-resistant schizophrenia (TRS). However, whether there is a critical …

Background The comparative antidepressant effects of clozapine and other atypical
antipsychotics for schizophrenia remain elusive, leading us to examine this question using …

The search for clinical outcome predictors for schizophrenia is as old as the field of
psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors …

Contemporary analyses demonstrate an early response to antipsychotic treatment in non-
refractory schizophrenia. The profile of response to clozapine is unknown. We used meta …

Relationships between symptom profile and clozapine response were studied. Symptom
scores on the Scale for the Assessment of Positive Symptoms and the Scale for the …

Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its
serum levels in patients with treatment-resistant schizophrenia. Although the relationship …

The aim of our study was to evaluate the effectiveness of lurasidone augmentation of
clozapine in treatment-resistant schizophrenia (SZ) in a retrospective chart review. From the …